Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

G.J. Ossenkoppele, D.A. Breems, G. Stuessi, Y. van Norden, M. Bargetzi, B.J. Biemond, P.A. von dem Borne, Y. Chalandon, J. Cloos, D. Deeren, M. Fehr, B. Gjertsen, C. Graux, G. Huls, J.J.J.W. Janssen, A. Jaspers, M. Jongen-Lavrencic, E. de Jongh, S.K. Klein, M. van der KliftM.V. Kooy, J. Maertens, L. Micheaux, M.W.M. van der Poel, A. van Rhenen, L. Tick, P. Valk, M.C. Vekemans, W.J.F.M. van der Velden, O. de Weerdt, T. Pabst, M. Manz, B. Lowenberg, H.a.v.e.l.a.n.g.e. Havelange, I. Moors, F. van Obberg, J.A. Maertens, B. Hodossy, S. Vansteenweghen, L. Lammertijn, A. Sonet, A. Triffet, B.T. Gjertsen, J. Passweg, D. Heim, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1751-1759
Number of pages9
JournalLeukemia
Volume34
Issue number7
DOIs
Publication statusPublished - 1 Jul 2020

Keywords

  • acute myeloid-leukemia
  • adults
  • high-dose lenalidomide
  • therapy
  • THERAPY
  • ADULTS
  • ACUTE MYELOID-LEUKEMIA
  • HIGH-DOSE LENALIDOMIDE

Cite this